Global Congestive Heart Failure Drugs market to grow at a CAGR of 9.47 percent by 2019
Single User License - $2500 Site User License - $2800 Corporate User License - $3500 Publication Date - Jan 2015 Pages - 116 To know more details, email to debora@reportstack.com
Contact: debora@reportstack.com Reportstack Market Research
Summary ď ś Congestive heart failure is a serious and complex condition in which the heart muscles are either damaged or have to work too hard. Although the heart beats, the damaged heart muscles are too weak to pump sufficient oxygen-rich blood to and from the body. ACE inhibitors/ARB antagonists, beta-adrenergic receptor blocking agents, diuretics, and inotropic drugs are the medications available for the treatment of congestive heart failure.
Contact: debora@reportstack.com Reportstack Market Research
Key Regions • Americas • APAC • EMEA
Contact: debora@reportstack.com Reportstack Market Research
Key vendors • AstraZeneca • Bristol-Myers Squibb • GSK • Merck & Co. • Mylan • Novartis • Pfizer • Sanofi • Valeant Pharmaceuticals
Contact: debora@reportstack.com Reportstack Market Research
Key Questions Answered in this Report • What will the market size be in 2019 and what will the growth rate be? • What are the key market trends? • What is driving this market? • What are the challenges to market growth? • Who are the key vendors in this market space? • What are the market opportunities and threats faced by the key vendors? • What are the strengths and weaknesses of the key vendors? Contact: debora@reportstack.com Reportstack Market Research
If you are interested...
Contact : Debora White Email: debora@reportstack.com Ph:+1-888-789-6604 http://www.reportstack.com
Contact: debora@reportstack.com Reportstack Market Research